Prognostic Impact of Histologic Subtyping of Adult Renal Epithelial Neoplasms: An Experience of 405 Cases

By Mahul B. Amin, Mitual Amin, P. Tamboli, J. Javidan, H. Stricker, M. Venturina, A. Deshpande, M. Menon. American Journal of Surgical Pathology, 2002

764 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/67fc42a3a00e746894171d0ee93652fe7febd44e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. W. Marston Linehan
2. Matthew Meyerson
3. Peter W. Laird
4. Chad Creighton

In Molecular Biology

1. Hui Shen
2. Peter W. Laird
3. W. Marston Linehan
4. P. Park
5. Michael Biehl
6. Matthew Meyerson
7. Chad Creighton
8. Preethi H. Gunaratne

Citations in the corpus

• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. (2006, result): “Elucidation of the different histologic subtypes of RCC indicates that there are distinct molecular mechanisms responsible for tumor growth, and that patients with different subtypes may have variable prognoses and may respond differently to treatment.(22) However, in this study, the antitumor effec”
• The somatic genomic landscape of chromophobe renal cell carcinoma (2014, background): “Although ChRCC typically exhibits an indolent pattern of local growth, with greater than 90% 10-year cancer-specific survival (Amin et al., 2002; Przybycin et al., 2011), aggressive features and metastasis can occur.”